NCT01676922

Brief Summary

This observational study will evaluate the use of Avastin (bevacizumab) and conventional chemotherapy in patients \>/= 70 years of age with previously untreated metastatic colorectal cancer. Data will be collected from each patient from initiation of treatment until disease progression occurs (minimum follow-up 12 months).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
256

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2011

Typical duration for all trials

Geographic Reach
1 country

33 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2011

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

August 27, 2012

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 31, 2012

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2015

Completed
Last Updated

November 2, 2016

Status Verified

November 1, 2016

Enrollment Period

3.8 years

First QC Date

August 27, 2012

Last Update Submit

November 1, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Treatment duration in patients receiving chemotherapy with Avastin as first-line therapy in daily clinical practice

    approximately 24 months

Secondary Outcomes (5)

  • Treatment duration in patients receiving chemotherapy alone as first-line therapy in daily clinical practice

    approximately 24 months

  • Safety: Incidence of adverse events/adverse events of special interest

    approximately 24 months

  • Clinical/demographic patient characteristics at baseline

    approximately 24 months

  • Dosage/regimen

    approximately 24 months

  • Correlation between Comprehensive Geriatric Assessment (CGA) scores and initial treatment

    approximately 24 months

Study Arms (1)

Cohort

Eligibility Criteria

Age70 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients \>/= 70 years of age with previously untreated metastatic colorectal cancer suitable to receive chemotherapy with or without Avastin

You may qualify if:

  • Adult patients, \>/ 70 years of age
  • Previously untreated metastatic colorectal cancer
  • Patient considered suitable to receive chemotherapy with or without Avastin

You may not qualify if:

  • Participation in any other clinical trial or study with the exception of participation in registries

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (33)

Unknown Facility

Aalst, 9300, Belgium

Location

Unknown Facility

Antwerp, 2020, Belgium

Location

Unknown Facility

Assebroek, 8310, Belgium

Location

Unknown Facility

Bonheiden, 2820, Belgium

Location

Unknown Facility

Bornem, 2880, Belgium

Location

Unknown Facility

Brasschaat, 2930, Belgium

Location

Unknown Facility

Bruges, 8000, Belgium

Location

Unknown Facility

Brussels, 1070, Belgium

Location

Unknown Facility

Brussels, 1090, Belgium

Location

Unknown Facility

Brussels, 1200, Belgium

Location

Unknown Facility

Ghent, 9000, Belgium

Location

Unknown Facility

Haine-Saint-Paul, 7100, Belgium

Location

Unknown Facility

Hasselt, 3500, Belgium

Location

Unknown Facility

Hornu, 7301, Belgium

Location

Unknown Facility

Ieper, 8900, Belgium

Location

Unknown Facility

Kortrijk, 8500, Belgium

Location

Unknown Facility

Leuven, 3000, Belgium

Location

Unknown Facility

Lier, 2500, Belgium

Location

Unknown Facility

Liège, 4000, Belgium

Location

Unknown Facility

Mechelen, 2800, Belgium

Location

Unknown Facility

Mons, 7000, Belgium

Location

Unknown Facility

Mont-godinne, 5530, Belgium

Location

Unknown Facility

Namur, 5000, Belgium

Location

Unknown Facility

Ostend, 8400, Belgium

Location

Unknown Facility

Oudenaarde, 9700, Belgium

Location

Unknown Facility

Roeselare, 8800, Belgium

Location

Unknown Facility

Ronse, 9600, Belgium

Location

Unknown Facility

Seraing, 4100, Belgium

Location

Unknown Facility

Sint-Niklaas, 9100, Belgium

Location

Unknown Facility

Tongeren, 3700, Belgium

Location

Unknown Facility

Turnhout, 2300, Belgium

Location

Unknown Facility

Verviers, 4800, Belgium

Location

Unknown Facility

Wilrijk, 2610, Belgium

Location

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Study Officials

  • Clinical Trials

    Hoffmann-La Roche

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 27, 2012

First Posted

August 31, 2012

Study Start

August 1, 2011

Primary Completion

May 1, 2015

Study Completion

May 1, 2015

Last Updated

November 2, 2016

Record last verified: 2016-11

Locations